CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 95 enrolled
Drug / intervention
Zinc Gluconate +1 moredrug
Likely dose
Zinc Gluconate 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05085834
NCT05085834Early Ph 1Completed
CompareCT.gov

Zinc Effect on Inflammation and Cardiovascular Risk in HIV

University Hospitals Cleveland Medical Center·interventional·Posted Oct 20, 2021·Updated Jun 12, 2025

In Brief

A Early Phase 1 clinical trial evaluating Zinc Gluconate and Placebo for Inflammation and 2 related conditions. Completed, enrolled 95 participants across 1 site.

Detailed Summary

To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Cardiovascular Diseases, Zinc Deficiency
CountriesUnited States
CollaboratorsCase Western Reserve University, National Center for Complementary and Integrative Health (NCCIH)

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedOct 20, 2021
Enrollment StartJan 22, 2020
Primary CompletionAug 2, 2024
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 4.7 years ago

Interventions

Zinc Gluconatedrug

Two 45 mg capsules once daily

Placebodrug

Two placebo capsules once daily